Atacem Mert Aytekin

Dr. Atacem Mert Aytekin

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AAAtacem Mert Aytekin
Atacem Mert Aytekin
YAYagmur Arslan
Yagmur Arslan
UAUtku Akgör
Utku Akgör
MCMURAT CENGIZ
MURAT CENGIZ
BABanu Boso Aslantas
Banu Boso Aslantas
OKOguzhan Kuru
Oguzhan Kuru
Background/objectives: The study aimed to present cases of malignant struma ovarii from seven centers in Türkiye and evaluate them within the context of the existing literature. Methods: We retrospectively analyzed clinical data from 17 patients treated at seven centers, focusing on clinical features, surgical management, pathology, thyroid function, adjuvant treatment, and outcomes. Additionally, a literature review including eight studies with 178 patients was conducted. Results: The mean age of patients was 44.7 years, with a mean tumor size of 9.2 cm. Elevated Ca 125 was found in 33.3% of patients, while thyroid function abnormalities and hyperthyroidism signs were rare. Pelvic pain and menstrual irregularities were common presenting symptoms. A total of 16 patients (94.1%) had unilateral tumors. Total abdominal hysterectomy with bilateral salpingo-oophorectomy and unilateral salpingo-oophorectomy were the most frequent surgical approaches. Histopathology predominantly showed classical papillary thyroid carcinoma (13 patients, 76%). All patients were FIGO stage I, with no metastasis. Thyroidectomy was performed in seven patients, identifying two concurrent thyroid cancers. Four patients received adjuvant radioactive iodine therapy. During a median follow-up of 43 months, no deaths and one recurrence were observed. The literature review showed a diagnosis age ranging 43–53 years and papillary thyroid carcinoma as the most common subtype. Thyroidectomy and RAI treatment were selectively applied. Among the reported studies, recurrence occurred in 7 of 76 patients (9.2%), while 5-year disease-free and overall survival rates exceeded 94% and 100%, respectively. BRAF mutations were uncommon. Conclusions: Malignant struma ovarii is a rare tumor with a favorable prognosis when diagnosed early and managed appropriately.

1 June 2026 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
AAAtacem Mert Aytekin
Atacem Mert Aytekin
HUHevra Ekin Ulusoy
Hevra Ekin Ulusoy
MEMehtap Akin Efe
Mehtap Akin Efe
CYCenk Yasa
Cenk Yasa
ABAhmet Buyukoren
Ahmet Buyukoren


19 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
YAYagmur Arslan
Yagmur Arslan
IEIpek Betul Ozcivit Erkan
Ipek Betul Ozcivit Erkan
AAAtacem Mert Aytekin
Atacem Mert Aytekin
CSCansu Turker Sarıcoban
Cansu Turker Sarıcoban
Abdullah Serdar AçıkgözAbdullah Serdar Açıkgöz
Abdullah Serdar Açıkgöz
OKOguzhan Kuru
Oguzhan Kuru
Background/Objectives: Ovarian germ cell tumors are rare, and determining prognostic factors is crucial for individualizing management strategies. We aimed to determine an optimal neutrophil-to-lymphocyte ratio (NLR) cut-off value for predicting survival outcomes in malignant ovarian germ cell tumors, and to evaluate the prognostic significance of NLR in these tumors. Methods: This retrospective cohort study included women diagnosed with malignant ovarian germ cell tumors who underwent surgery at Istanbul University-Cerrahpasa between 2000 and 2024. Patients with benign tumors; incomplete follow-up; inaccessible data; history of hematological or rheumatic diseases; inflammatory conditions such as diabetes mellitus, asthma, or renal failure; as well as those with acute/chronic infections or sepsis were excluded. Data collected included demographic characteristics, surgical and pathological findings, chemotherapy details, disease progression, survival outcomes, and laboratory values at preoperative, postoperative, and post-chemotherapy time points. The NLR was calculated and compared for overall survival and disease-free survival. Results: The study included 44 patients with a pathologically confirmed diagnosis of malignant ovarian germ cell tumors. The NLR cut-off value for survival prediction was determined as 3.69 using the ROC curve. The effect of preoperative NLR on overall survival was found to be significant. The median overall survival was significantly lower in the group with NLR ≥ 3.69 (153.2 months) compared to the group with NLR < 3.69 (234 months) (p = 0.010). However, there was no statistically significant difference in median disease-free survival between the NLR ≥ 3.69 group (159.3 months) and the NLR < 3.69 group (215 months). Conclusions: The preoperative NLR was found to have a significant impact on overall survival but not on disease-free survival. A cut-off value of 3.69 can be used to assess short survival time.

11 February 2026 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
HUHevra Ekin Ulusoy
Hevra Ekin Ulusoy
YMYagmur Minareci
Yagmur Minareci
KKKucukgergin Kucukgergin
Kucukgergin Kucukgergin
AAAbdurrahman Fatih Aydin
Abdurrahman Fatih Aydin
HSHamdullah Sozen
Hamdullah Sozen
STSamet Topuz
Samet Topuz
Background: Endometrial cancer (EC) is the second most common gynecological malignancy and remains a major contributor to morbidity and mortality among women worldwide. Current diagnostic and prognostic tools have limited accuracy, highlighting the need for reliable, non-invasive biomarkers. Non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), have emerged as promising candidates. This study aimed to investigate serum lncRNA HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) and miR-182-5p expression levels in EC and evaluate their diagnostic value and association with clinicopathological features. Methods: This prospective cohort study analyzed serum samples that were prospectively collected from 73 women with histologically confirmed EC and 76 controls with non-malignant gynecological conditions. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to quantify serum lncRNA HOTAIRM1 and miR-182-5p expression levels. Associations with clinicopathological parameters and diagnostic performance were evaluated. Results: Serum expression levels of lncRNA HOTAIRM1 were significantly higher in EC patients (median [interquartile range (IQR)]: 1.36 [0.74–3.37]) than in controls (1.03 [0.58–2.03]; p = 0.043), whereas miR-182-5p levels showed no significant difference (p = 0.327). Receiver operating characteristic (ROC) curve analysis demonstrated that serum lncRNA HOTAIRM1 had high specificity (93.2%) but low sensitivity (29.6%) for EC diagnosis. No significant associations were identified between either biomarker or clinicopathological variables (p > 0.05). Conclusions: This study provides one of the first evaluations of circulating lncRNA HOTAIRM1 and miR-182-5p in serum samples from patients with EC. Our findings suggest that serum lncRNA HOTAIRM1, but not miR-182-5p, may serve as a potential non-invasive biomarker for EC. Although its limited sensitivity restricts its role as a standalone diagnostic tool, its high specificity supports potential clinical relevance. These preliminary results should be interpreted with caution, as they represent an initial exploratory analysis of circulating lncRNA HOTAIRM1 and miR-182-5p in EC.

8 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AAAtacem Mert Aytekin
Atacem Mert Aytekin
IEIpek Betul Ozcivit Erkan
Ipek Betul Ozcivit Erkan
SOSeyma Okumus
Seyma Okumus
BSBilgehan Saglik
Bilgehan Saglik
AYAyşe YAVUZ
Ayşe YAVUZ
OKOguzhan Kuru
Oguzhan Kuru
Background/Objectives: Uterine adenosarcoma is a rare uterine malignancy with limited evidence on prognostic factors and long-term outcomes. We aimed to evaluate clinicopathological characteristics, treatment patterns, oncologic outcomes, and prognostic factors associated with disease-free survival (DFS) and overall survival (OS) in patients with uterine adenosarcoma. Methods: This multicenter retrospective cohort study included 43 patients with histopathologically confirmed uterine adenosarcoma who underwent primary surgery at seven tertiary referral centers in Türkiye between 2016 and 2026. Clinicopathological features, treatment modalities, recurrence patterns, and survival outcomes were assessed. Survival was analyzed using Kaplan–Meier and log-rank methods, and multivariable Cox proportional hazards regression was performed to identify independent prognostic factors. Results: The mean age at diagnosis was 59.1 ± 10.8 years, and 83.7% of patients were postmenopausal. Pelvic pain (62.8%) and abnormal uterine bleeding (60.5%) were the most common presenting symptoms. Most patients (79.1%) underwent laparotomy, and 79.1% had stage I disease. Sarcomatous overgrowth (SO) was present in 44.1% and lymphovascular space invasion (LVSI) in 18.6%. During a median follow-up of 72 months, 34.9% experienced recurrence, most commonly in the pelvis. The five-year DFS and OS rates were 59.9% and 80.4%, respectively. SO was independently associated with DFS (HR 4.41, 95% CI 1.21–16.08; p = 0.025) and OS (HR 10.23, 95% CI 1.16–89.80; p = 0.036), while LVSI was independently associated with OS (HR 11.17, 95% CI 1.34–93.14; p = 0.026). Conclusions: Uterine adenosarcoma showed favorable long-term survival but substantial recurrence risk. SO and LVSI may have potential prognostic relevance and could contribute to postoperative risk assessment and individualized follow-up.